H7型流感快檢試劑盒

廣州健侖生物科技有限公司

廣州健侖長(zhǎng)期供應(yīng)各種流感檢測(cè)試劑，包括進(jìn)口和國(guó)產(chǎn)的品牌，主要包括日本富士瑞必歐、日本生研、美國(guó)BD、美國(guó)NovaBios、美國(guó)binaxNOW、英國(guó)clearview、凱必利、廣州創(chuàng)侖等主流品牌。

H7型流感快檢試劑盒

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

人類有許多慢性病，像多發(fā)性硬化癥、I型糖尿病和類風(fēng)濕性關(guān)節(jié)炎，是由免疫系統(tǒng)以某種方式“濫殺無(wú)辜”引起的，這種免疫系統(tǒng)傷害自身組織和器官的疾病被稱為自體免疫疾病。目前，自體免疫疾病尚無(wú)法治愈，而現(xiàn)有的多數(shù)藥物則無(wú)法區(qū)分正常免疫細(xì)胞和會(huì)發(fā)動(dòng)自體攻擊的免疫細(xì)胞，所以它們雖然可暫時(shí)緩解癥狀，但也消滅了抑制有害細(xì)菌和病毒所必需的正常免疫細(xì)胞，從長(zhǎng)期看會(huì)讓病人更脆弱。
研究負(fù)責(zé)人、美國(guó)國(guó)家衛(wèi)生研究院黏膜免疫研究室主任陳萬(wàn)軍對(duì)新華社記者說(shuō)，自體免疫疾病的一個(gè)共同的重要發(fā)病機(jī)理是，患者免疫系統(tǒng)的正常平衡被破壞，導(dǎo)致患者體內(nèi)充斥著大量炎癥細(xì)胞和因子。所以理論上zui有效的治療方法應(yīng)該是，首先把這個(gè)已失去平衡、免疫反應(yīng)過(guò)強(qiáng)的狀態(tài)打破，然后再重新誘導(dǎo)免疫系統(tǒng)建立一個(gè)新的秩序，即恢復(fù)正常的平衡狀態(tài)，讓免疫細(xì)胞對(duì)自己的組織和器官耐受而不是破壞。“簡(jiǎn)單地說(shuō)，基本原理就是‘打破一個(gè)舊世界，建立一個(gè)新世界’”。
陳萬(wàn)軍等人采取的新方案是，首先誘導(dǎo)實(shí)驗(yàn)鼠的自身免疫細(xì)胞凋亡，讓這些細(xì)胞被體內(nèi)一種叫做巨噬細(xì)胞的吞噬細(xì)胞“吃掉”，之后巨噬細(xì)胞會(huì)產(chǎn)生一種重要的免疫調(diào)控抑制因子TGFβ。TGFβ在體內(nèi)會(huì)形成一個(gè)免疫調(diào)控的微環(huán)境，在這種微環(huán)境下再注射一種蛋白多肽，去刺激新的未分化的“原始”或“處女”T細(xì)胞，這些T細(xì)胞在TGFβ占優(yōu)勢(shì)的微環(huán)境中，會(huì)分化成免疫調(diào)節(jié)T細(xì)胞，而不是破壞自身組織和器官的炎癥細(xì)胞。
他說(shuō)：“這些免疫調(diào)節(jié)細(xì)胞會(huì)進(jìn)入相應(yīng)的、有自身免疫病的組織和器官，防止和抑制破壞自身組織的免疫炎癥細(xì)胞的產(chǎn)生或發(fā)揮功能，從而讓疾病得到緩解甚至治愈。”

There are many chronic diseases in humans, such as multiple sclerosis, type I diabetes and rheumatoid arthritis, which are caused by the immune system somehow "killing innocent people" and diseases of the immune system that harm their own tissues and organs are said For autoimmune diseases. At present, autoimmune diseases are not yet curable, and most existing drugs can not distinguish between normal immune cells and autoimmune immune cells, so although they can temporarily relieve symptoms, but also eliminate the necessary to inhibit harmful bacteria and viruses Normal immune cells, in the long run will make the patient more vulnerable.
Chen Wanjun, head of the study and Director of the Mucosal Immunization Laboratory at the National Institutes of Health, told Xinhua that a common and important pathogenesis of autoimmune diseases is the breakdown of the normal balance of the patient's immune system, resulting in the patient being flooded with inflammatory cells And factor. Therefore, in theory, the most effective treatment should be the first to break the balance of the immune response is too strong, and then re-induce the immune system to establish a new order, that is, to restore normal equilibrium, so that immune cells on their own Tissue and organs are tolerant rather than destructive. "Simply put, the basic principle is to 'break an old world and build a new world'".
Chen Wanjun and others to take a new program is to first induce experimental mouse immune cell apoptosis, so that these cells are the body of a phagocyte called macrophage eaten, macrophages will produce an important immune Regulatory inhibitor of TGFβ. TGFβ forms an immunomodulatory microenvironment in the body in which a protein polypeptide is reinjected to stimulate new undifferentiated "virgin" or "virgin" T cells that predominate in TGFβ In the microenvironment, it differentiates into immunoregulatory T cells rather than inflammatory cells that destroy their own tissues and organs.
"These immune-regulating cells get into the corresponding autoimmune-damaged tissues and organs, preventing and inhibiting the production or functioning of immune-inflammatory cells that destroy their tissues, thereby allowing the disease to be relieved or even healed."